Gracell Biotechnologies acquisition marks China’s growing importance to the Anglo-Swedish drugmaker
AstraZeneca has struck a deal to buy a Chinese cancer therapy company for up to $1.2bn (£950m), as Britain’s biggest drugmaker expands its footprint in its second-largest market.
The Anglo-Swedish pharmaceutical firm announced on Tuesday it would acquire Gracell Biotechnologies, which is focused on a type of cancer therapy known as CAR-T that modifies a patient’s cells to fight the disease.
About Author
More Stories
Bodies recovered from illegal goldmine in South Africa where many feared dead
Italy seeks to protect restaurants and hotels from fake and paid-for reviews
‘Don’t allow you to go to the bathroom’: big tech’s call center workers in Greece on strike